Health Catalyst (NASDAQ:HCAT) Given New $10.50 Price Target at Citigroup

Health Catalyst (NASDAQ:HCAT) had its price objective lifted by analysts at Citigroup from $9.00 to $10.50 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price target would indicate a potential upside of 24.26% from the company’s current price.

HCAT has been the subject of several other reports. JPMorgan Chase & Co. lifted their price objective on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Evercore ISI boosted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Piper Sandler cut their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Finally, Stephens decreased their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.71.

Health Catalyst Stock Down 2.4 %

Shares of HCAT stock opened at $8.45 on Wednesday. Health Catalyst has a 52-week low of $5.42 and a 52-week high of $11.41. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm’s 50-day moving average is $8.13 and its 200-day moving average is $7.20.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same quarter in the prior year, the firm earned ($0.22) earnings per share. Health Catalyst’s revenue for the quarter was up 3.5% on a year-over-year basis. As a group, equities research analysts forecast that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the sale, the chief operating officer now owns 134,899 shares of the company’s stock, valued at approximately $1,036,024.32. This trade represents a 3.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,068 shares of company stock valued at $257,555. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Health Catalyst

Hedge funds have recently made changes to their positions in the stock. Fred Alger Management LLC purchased a new position in shares of Health Catalyst in the 3rd quarter worth about $6,858,000. Millrace Asset Group Inc. bought a new position in shares of Health Catalyst during the 3rd quarter valued at $1,568,000. Primecap Management Co. CA raised its position in Health Catalyst by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after purchasing an additional 25,000 shares during the period. Intech Investment Management LLC bought a new stake in Health Catalyst in the third quarter worth $145,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Health Catalyst by 118.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 131,532 shares of the company’s stock valued at $1,071,000 after buying an additional 71,201 shares during the period. 85.00% of the stock is owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.